Question 1

What does Lutris Pharma do?

Accepted Answer

Lutris Pharma is a biotechnology company dedicated to supporting patients and physicians in management of skin toxicities that result from use of certain cancer drugs. Learn more about our lead asset LUT014.

Question 2

Is Lutris publicly traded?

Accepted Answer

Lutris is a privately held company funded by lead investors. See our Investors page for more.

Question 3

What is LUT014 and how does it work?

Accepted Answer

LUT014 is a B-RAF inhibitor that is formulated as a gel. When applied directly to the skin it blocks B-RAF, a protein in the MAPK pathway, and can help reduce acneiform rash resulting from certain cancer treatments without interfering with the cancer drug's effect on the tumor.

Question 4

How is LUT014 different from existing topical treatments (steroids, antibiotics)?

Accepted Answer

LUT014 is a B-RAF inhibitor that acts directly on the same pathway as certain cancer drugs. It therefore addresses the mechanism of action that leads to the rash. Other treatment options typically address symptoms and not the underlying mechanism that leads to the rash.

Question 5

Is LUT014 a systemic or topical therapy?

Accepted Answer

LUT014 is formulated as a gel and applied topically (to the skin).

Question 6

What are the key publications or data behind the program?

Accepted Answer

LUT014 was studied in Phase 1 and Phase 2 clinical trials. For more information see our publications page.

Question 7

What stage of development is LUT014 in?

Accepted Answer

LUT014 was studied in Phase 1 and Phase 2 clinical trials. For more information see our publications page.

Question 8

What indications are you currently studying?

Accepted Answer

Currently Lutris Pharma is developing LUT014 for the treatment of acneiform rash induced by certain anti-cancer drugs. To learn more about our development plans, see our lead program page.

Question 9

Who is eligible to participate?

Accepted Answer

If you have any questions about our trial, please contact us.

Question 10

How can a patient or physician enroll?

Accepted Answer

If you have any questions about our trial, please contact us.

Question 11

Is the drug commercially available?

Accepted Answer

LUT014 is an investigational drug. It has not been approved by the U.S. Food and Drug Administration (FDA) for use by the general public. It is not approved as safe or effective, and is currently for use only in clinical trials or through approved expanded access programs. The safety and effectiveness of this product have not been fully established.

Question 12

Are you open to licensing or partnership discussions?

Accepted Answer

Lutris Pharma is happy to discuss collaboration opportunities to benefit patients. Visit our contact us page to get in touch.

Frequently Asked Questions

About Lutris

Science & Technology

Clinical Trials / Pipeline

Partnering & Careers